The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology. The fourth leading cause of ...

Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filings ...

and advanced cervical cancer. In the?US, the generic name for Libtayo in its approved?indications is cemiplimab-rwlc, with rwlc as the suffix designated in accordance with Nonproprietary Naming of ...

The Basser Center at the University of Pennsylvania is evaluating the tolerability and immunogenicity of INO-5401 in a Phase 1 study exploring the potential to prevent cancer in people with BRCA1 ...

A new research paper was published in Oncoscience's Volume 12 on January 20, 2025, titled "Maternal, delivery and neonatal outcomes in women with cervical cancer. A study of a population database." ...

A new report explores the disproportionately high death rate among Black women in the Delta from cervical cancer.

A new research paper was published in Oncoscience’s Volume 12 on January 20, 2025, titled “Maternal, delivery and neonatal ...

Cervical cancer is caused by persistent infection due to human papillomavirus (HPV), leading to abnormal cell formation in the cervix. Some of the common symptoms of cervical cancer are vaginal ...

Consider this a public cervix announcement. The American Cancer Society made a dire prediction — nearly 13,400 cases of invasive cervical cancer will be diagnosed this year and about 4,300 women ...

HPV vaccination rates are lower in Wyoming than other states. The vaccine can help prevent cervical cancer in women.

This study is unique in that we are doing it through the lens of Indigenous people and researchers.” -- Naomi Lee, Ph.D., an ...